Celcuity's FDA approval of gedatolisib (REVTORPYK) marks a pivotal transition from clinical to commercial stage, but the company's financial position is severely strained. Operating losses have widened to -$66.1M in 2026Q2, and total debt surged to $754.4M, driving shareholders' equity negative at -$12.8M.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$1.21+19.9% vs -$1.51 | — vs $909,800 |
Q3 2026 Aug 13, 2026 | -$1.44-24.1% vs -$1.16 | — vs $4M |
Q2 2026 May 14, 2026 | -$0.97+6.7% vs -$1.04 | — vs $3M |
Q2 2026 Mar 25, 2026 | -$0.97+8.5% vs -$1.06 | — vs $1M |
Celcuity NASDAQ: CELC reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to an encouraging launch.
MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. REVTORPYK demonstrated strong efficacy and safety, especially versus existing PI3K-targeted regimens, but faces competition from established oral drugs like Truqap. Management targets $2.5 billion peak sales, but base case models suggest substantial upside even at $1.2 billion with current US-only assumptions.
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.
Benchmark CELC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Celcuity Inc. (CELC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $66.79 | $3.26B | -14.39 | — | — | -1522.54% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $21.50 | $3.5B | -26.04 | 48.29% | -229.92% | -25.74% | — | |
| $1.26 | $67.2M | -0.89 | — | — | -78.11% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — |
Celcuity Inc. (CELC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Celcuity Inc. (CELC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
Aug 13, 2026·SEC
Jul 15, 2026·SEC
Get notified when CELC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Celcuity Inc. (CELC) stock FAQ — growth, dividends, profitability & financials explained
No. Celcuity Inc. (CELC) reported a net loss of $256.0M over the trailing twelve months.
Celcuity Inc. (CELC) had a return on equity (ROE) of -1522.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Celcuity Inc. (CELC) had negative free cash flow of $213.5M over the trailing twelve months.
